SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Esperion Therapeutics, Inc. Announces Positive Topline Results from a Phase 2 Clinical Trial of ETC-1002 in Patients with Type 2 Diabetes